Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Veriheal

JULY 18, 2023

The recently proposed bipartisan bill pledges $75 million towards research into the therapeutic potential of psychedelic substances in treating post-traumatic stress disorder (PTSD). The Grant Program Details The heart of this landmark legislation lies in the development of a robust grant program. In a bold and unprecedented move, U.S.

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98

Cannabis Law Report

JUNE 4, 2021

Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Phase 2 trial underway. Clinical trial information: NCT03276572 ( [link] ). Actinium-225 radiolabeled J591 safe at tested dosage.

Data 100

Data Research and Development Clinical Trials Therapy 100

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JULY 28, 2021

The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. . – July 28, 2021) – PharmaDrug Inc.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I firmly believe the current downtrend in the industry is an overreaction to incredibly positive results from Compass Pathways 2b trial, which have clearly been misinterpreted. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JULY 8, 2021

(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.

Research and Development 85

Research and Development Pets Cannabinoids eCommerce 85

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Veriheal

FEBRUARY 9, 2023

Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. Magic Mushrooms: The Ticket to a Stress-Free MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

CannaTech

SEPTEMBER 23, 2019

This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Furthermore, pharmaceutical companies often fund and initiate randomised clinical trials to validate their drugs.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

AUGUST 10, 2021

Shanti”), and all its assets focused on psychedelic MDMA-based drug development. This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 51

DEA Clinical Trials THC Research and Development 51

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Still, research is ongoing. Parkinson’s disease and cannabis. The effectiveness of cannabis for Parkinson’s disease.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

MAY 29, 2022

is a Canadian company that researches, develops and grows psilocybin-producing mushrooms and functional mushrooms. And there are literally hundreds of trials that are being done, and more forthcoming.”. The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities. “I’m

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

The Cannigma

DECEMBER 14, 2021

HHC was synthesized in Adams’ laboratory as part of research to understand the active compounds in the cannabis plant. There are even a few third-party testing labs that are developing analytical methods to test and validate HHC sample identity and purity. HHC can be vaped or used in edibles and oils and tinctures (Shutterstock).

Research and Development 116

Research and Development Clinical Trials Cannabinoids THC 116

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. ABOUT ANANDA SCIENTIFIC.

Clinical Trials 40

Clinical Trials Treatment Research and Development Media 40

Cannabis Law Report

JULY 28, 2021

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Support Regulatory Affairs in the planning, development, and publishing of submissions.

Clinical Trials 81

Clinical Trials Research and Development Data Environment 81

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Once known solely as a party drug, ketamine is starting to earn a new reputation thanks to research efforts into its potentially medicinal qualities.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

DECEMBER 9, 2021

MindMed presented FDA with a working Indications for Use statement (IFU), and a development roadmap. FDA provided key feedback regarding the draft IFU and the research methods that will lay the foundation for regulatory submissions. ” About MindMed.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid. We look forward to Dr. Johnson’s expertise as we expand our mental health analytical platform and enter clinical trials.”

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

DECEMBER 26, 2021

EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial. . – December 16, 2021) – Entheon Biomedical Corp. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

AUGUST 23, 2021

Notwithstanding the limited impact of the Covid-19 pandemic on the Group’s activities, very good progress has been made on advancements across all four current drug development programmes and OCTP remains firmly on target to achieve its timeline to commercialisation as set out in its IPO Prospectus published in May of this year.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Numinus Wellness Inc.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Major research hospitals such as Montefiore in New York now use cannabis for treating cancer and HIV, as well as make new studies.

Treatment 49

Treatment Clinical Trials Research and Development Cannabinoids 49

Cannabis Law Report

JULY 25, 2022

together with research collaborators at the University of Auckland , have received NZ$1.44 million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). mentalhealth #help #lsd #menta … [link].

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Puff Puff Post

SEPTEMBER 16, 2019

Santé Cannabis, a pioneer in medical cannabis in Québéc , has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

SEPTEMBER 14, 2021

The new Radicle Science-OBX alliance fills an unmet need for rigorous scientific research in the cannabis industry and sets a new gold standard for CBD and minor cannabinoid product development.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52